FDA Details Expectations For Approval Of New Painkillers

Law360, New York (February 6, 2014, 8:33 PM EST) -- The U.S. Food and Drug Administration on Wednesday described its current expectations for development and testing of painkillers, outlining key standards for a drug class whose sometimes addictive properties have led to tremendous controversy and litigation.

In its draft guidance, the FDA discussed how its clinical trial demands will vary greatly depending on the type of painkiller or analgesic that is being studied. For example, a reformulated version of a previously approved medicine may need only one additional trial to prove safety and effectiveness, regulators said....
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.